Li Qiao, Prince Mark E P, Moyer Jeffrey S
University of Michigan Comprehensive Cancer Center, 1500 E Medical Center Dr., Ann Arbor, MI 48109, United States.
University of Michigan Comprehensive Cancer Center, 1500 E Medical Center Dr., Ann Arbor, MI 48109, United States.
Oral Oncol. 2015 Apr;51(4):299-304. doi: 10.1016/j.oraloncology.2014.12.005. Epub 2015 Jan 24.
To review the current state of immunotherapy of head and neck squamous cell carcinoma.
Review of the literature with emphasis on clinical trial data.
Patients with head and neck squamous cell carcinoma (HNSCC) have long been known to be immunosuppressed. This impairment of the immune system is believed, at least in part, to underlie the poor outcomes in this patient population. Modulating the immune system to improve cancer outcomes is an attractive concept in this difficult to treat population.
New studies have started to unravel the mechanisms of immunosuppression and new therapies are being developed to exploit this new information.
回顾头颈部鳞状细胞癌免疫治疗的现状。
回顾文献，重点关注临床试验数据。
长期以来已知头颈部鳞状细胞癌（HNSCC）患者存在免疫抑制。免疫系统的这种损害至少在一定程度上被认为是该患者群体预后不良的原因。在这个难以治疗的群体中，调节免疫系统以改善癌症预后是一个有吸引力的概念。
新的研究已开始揭示免疫抑制的机制，并且正在开发新的疗法以利用这些新信息。
